Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Work In Process: 2012-2018

Historic Work In Process for Lifecore Biomedical (LFCR) over the last 7 years, with Nov 2018 value amounting to $3.1 million.

  • Lifecore Biomedical's Work In Process fell 34.24% to $3.1 million in Q4 2018 from the same period last year, while for Nov 2018 it was $3.1 million, marking a year-over-year decrease of 34.24%. This contributed to the annual value of $3.7 million for FY2018, which is 6.53% up from last year.
  • Per Lifecore Biomedical's latest filing, its Work In Process stood at $3.1 million for Q4 2018, which was down 1.72% from $3.1 million recorded in Q3 2018.
  • Over the past 5 years, Lifecore Biomedical's Work In Process peaked at $13.0 million during Q4 2016, and registered a low of $1.9 million during Q2 2015.
  • Moreover, its 3-year median value for Work In Process was $3.5 million (2016), whereas its average is $4.2 million.
  • As far as peak fluctuations go, Lifecore Biomedical's Work In Process skyrocketed by 265.69% in 2016, and later plummeted by 63.95% in 2017.
  • Quarterly analysis of 5 years shows Lifecore Biomedical's Work In Process stood at $4.0 million in 2014, then declined by 11.86% to $3.6 million in 2015, then spiked by 265.69% to $13.0 million in 2016, then plummeted by 63.95% to $4.7 million in 2017, then crashed by 34.24% to $3.1 million in 2018.
  • Its Work In Process was $3.1 million in Q4 2018, compared to $3.1 million in Q3 2018 and $3.7 million in Q2 2018.